💊 Médicaments A-Z 🧬 Cibles 🛠 Outils 📚 Guides
Tous les médicaments Classes de médicaments Aires thérapeutiques Effets Indésirables
Guides Glossaire Chronologie
Comparaisons Parcours des médicaments Familles de médicaments
🇺🇸 English 🇰🇷 한국어 🇯🇵 日本語 🇨🇳 中文简体 🇪🇸 Español 🇧🇷 Português 🇮🇳 हिन्दी 🇸🇦 العربية 🇫🇷 Français 🇷🇺 Русский 🇩🇪 Deutsch 🇹🇷 Türkçe 🇻🇳 Tiếng Việt 🇮🇩 Bahasa Indonesia 🇹🇭 ไทย

Diltiazem Hydrochloride

CHEMBL1697 Phase 4 Approuvé Small molecule
Half-Life
—
Bioavailability
—
Protein Binding
—
Molecular Weight
451.0 g/mol
LogP
—
Phase
4

The hydrochloride salt form of diltiazem, the standard pharmaceutical preparation used in oral and injectable formulations for hypertension, angina, and arrhythmias. It slows conduction through the AV node of the heart and dilates arteries. Available in immediate and extended-release formulations for different clinical needs.

Masse moléculaire

451,0000 g/mol

TPSA

84,40 Ų

Aires thérapeutiques

Cardiovascular Disease Pain Management Gastroesophageal Reflux Disease Stroke Deep Vein Thrombosis / Pulmonary Embolism Obesity Type 2 Diabetes Hypertension Chronic Pain Hepatitis C Heart Failure Atrial Fibrillation Colorectal Cancer

Mécanisme d'action

Benzothiazepine calcium channel blocker.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Mécanisme

Benzothiazepine calcium channel blocker.

Structure 2D

SVG PNG

Cite this structure


                        

                            
                            
                        

                    

                


                
                

                    

                    

                        
Embed this structure

                        

                        

                            
                            
                        

                    

                

                

                
                

                    
SMILES

                    
COc1ccc([C@@H]2Sc3ccccc3N(CCN(C)C)C(=O)[C@@H]2OC(C)=O)cc1.Cl

                

                

                
                

                    
InChI

                    
InChI=1S/C22H26N2O4S.ClH/c1-15(25)28-20-21(16-9-11-17(27-4)12-10-16)29-19-8-6-5-7-18(19)24(22(20)26)14-13-23(2)3;/h5-12,20-21H,13-14H2,1-4H3;1H/t20-,21+;/m1./s1

                

                

                

                    
                    

                        
Molecular Formula

                        
C22H27ClN2O4S

                    

                    
                    

                        
HBD / HBA

                        
1 / 6

                    

                    
                    

                        
Liaisons Rotatives

                        
7

                    

                    
                    
                    

                        
Atomes Lourds

                        
30

                    

                    
                

            


            
            

                
                


    
    
        
    
    
    
No targets recorded

    
    
Target interaction data is not yet available for this drug.

    



                
            


            
            

                
                


    
    
        
    
    
    
No interactions recorded

    
    
Drug interaction data is not yet available for this compound.

    



                
            


            
            

                
                


    
    
        
    
    
    
No side effects recorded

    
    
Side effect data is not yet available for this drug.

    



                
            


            
            
            

                
Foire aux questions

                

                    
                    

                        
                        

                            
The hydrochloride salt form of diltiazem, the standard pharmaceutical preparation used in oral and injectable formulations for hypertension, angina, and arrhythmias. It slows conduction through the AV node of the heart and dilates arteries. Available in immediate and extended-release formulations for different clinical needs.

                        

                    

                    

                    

                    
                    

                        
                        

                            
Benzothiazepine calcium channel blocker.

                        

                    

                    

                    

                    

                        
                        

                            
Yes, Diltiazem Hydrochloride is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

                        

                    

                

            

            

            
            

            
            

            
            
{# References & Data Sources section for drug detail pages.
   Renders standard pharmacological database links plus the drug's data_sources field. #}


    
References & Data Sources

    
    
        
        
  • 
            
            
                ChEMBL — European Bioinformatics Institute (EBI).
                CHEMBL1697.
                Open-access bioactivity database.
            
        
    • 
        
        
        
  • 
            
            
                PubChem — National Center for Biotechnology Information (NCBI).
                CID 62920.
                Chemical information database.
            
        
    • 
        
        
        
        
    

    
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.




        


        
        
    


    



    
Avertissement médical

    

        This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.
    

    

        Data sources:
        ChEMBL,
        PubChem,
        DailyMed.